calcium carbonate has a significant effect on imatinib pharmacokinetics. Methods Eleven healthy subjects were enrolled in a 2-period, open-label, single-institution, randomized crossover, fixed-schedule study. In one period, each subject received 400 mg of imatinib p.o. In the other period, 4,000 mg calcium carbonate (tums ultra ® ) was administered p.o. 15 min before 400 mg of imatinib. Plasma concentrations of imatinib and its active N-desmethyl metabolite CGP74588 were assayed by LC-mS; data were analyzed non-compartmentally and compared after log transformation. Results Calcium carbonate administration did not significantly affect the imatinib area under the plasma concentration versus time curve (auC) (41.2 μg/mL h alone vs. 40.8 μg/mL h with calcium carbonate, P = 0.99), maximum plasma concentration (C max ) (2.35 μg/mL alone vs. 2.39 μg/mL with calcium carbonate, P = 0.89). Conclusions Our results indicate that the use of calcium carbonate does not significantly affect imatinib pharmacokinetics.
Introduction
Imatinib mesylate (Gleevec ® , Glivec ® ) is widely used to treat chronic myeloid leukemias (CmL) based on its inhibition of Bcr-abl-the tyrosine kinase encoded by the Philadelphia chromosome created by reciprocal translocation between chromosome 9 and 22-and to treat gastrointestinal stromal tumors (GISt) based on its inhibition of c-KIt [3, 5, 6] . Common side effects of imatinib therapy include dyspepsia (18 %) and nausea (43 %) [6] , for which Abstract Purpose Imatinib mesylate (Gleevec ® /Glivec ® ) has revolutionized the treatment of chronic myeloid leukemias and gastrointestinal stromal tumors, and there is evidence for an exposure response relationship. Calcium carbonate is increasingly used as a calcium supplement and in the setting of gastric upset associated with imatinib therapy. Calcium carbonate could conceivably elevate gastric ph and complex imatinib, thereby influencing imatinib absorption and exposure. We aimed to evaluate whether use of patients may self-administer over-the-counter remedies, including calcium carbonate. In addition, nearly a quarter of the population over age 20 has been reported to use calcium supplements, a number that is expected to continue to rise in parallel with the number of older adults at risk for osteoporosis [9, 11] . Calcium carbonate may alter the pharmacokinetics (PK) of imatinib as it can (1) increase the ph of the stomach content; (2) delay gastric emptying; and (3) supply calcium ions capable of forming non-absorbable complexes (e.g., as occurs with tetracycline antibiotics). Consequently, the absorption of imatinib may be decreased by calcium salts taken for either gastric upset or calcium supplementation, resulting in sub-therapeutic concentrations of imatinib, potentially leading to selection of resistant subclones and ultimately relapse.
although prospective, confirmatory studies are lacking, there is evidence that imatinib trough levels are associated with clinical benefit in patients with advanced GISt and with response in patients with CmL [4, 8] . therefore, it is important to document whether coadministration compromises absorption and/or exposure in subjects, which likely would lead to a reduction in efficacy.
Methods

Subjects
this pharmacokinetic study aimed to enroll up to 20 subjects for a maximum of 12 evaluable healthy subjects (6 men, 6 women; ≥18 years of age; body mass index (BmI) <31 kg/m 2 ). Subjects signed an informed consent that had been approved by the university of Pittsburgh Institutional review Board. this trial was listed on Clinicaltrials.gov under identifier nCt00732784. Exclusion criteria were defined as follows and applied when considered clinically significant: abnormal bone marrow function (defined as leukocyte, neutrophil, or platelet counts outside the limits of the institution's normal ranges); renal dysfunction (proteinuria, estimated creatinine clearance <60 mL/ min/1.73 m 2 ); impaired hepatic function (liver enzymes or bilirubin > the normal upper limit); pregnancy or breastfeeding; use of any medications (including over-the-counter products, herbal products, or mineral supplements) within 2 weeks of start of the study, or an investigational new drug within 28 days of start of the study. Daily multivitamin preparations or oral contraceptives (for women) were allowed. Study design the study followed a 2-period, open-label, randomized crossover, fixed-sequence design and was powered at an effect size of 1.3 to detect a 13 % difference in imatinib auC with 80 % power and a 5 % type I error, assuming a within-subject variability of approximately 10 %. In one period, each subject received 400 mg of imatinib (Gleevec ® ; novartis Pharmaceuticals Corp, East hanover, nJ, uSa) p.o. with 200 mL of water, while in the other period, 4,000 mg of calcium carbonate (tums ultra 1000 ® ) was administered p.o. 15 min prior to the imatinib dose. the two imatinib doses were separated by a washout of at least 14 days.
Pharmacokinetic sampling and bioanalysis
Subjects were asked to fast starting midnight before dosing and were given a normal diet on the first day of pharmacokinetic sampling. Venous blood samples (N = 12 per subject, 6 mL each) were drawn into heparinized Vacutainer™ tubes before and at 0.5, 1, 2, 3, 4, 5, 6, 8, 24, 48, and 72 h after imatinib administration. Blood samples were centrifuged at 4 °C, 3,000×g for 10 min, and the resulting plasma was aspirated and stored at −20 °C or colder until quantitative analysis.
Plasma samples were analyzed for concentrations of imatinib and its active N-desmethyl metabolite (CGP74588) using a previously reported LC-mS method [7, 10] , which is linear over the range of 10-1,000 ng/mL and exhibited acceptable performance (imatinib: accuracy 13.1-9.8 %; precision <6.8 % CV; CGP74588: accuracy 5.3-6.7 %; precision <15.0 % CV).
Pharmacokinetic data analysis the pharmacokinetic parameters of imatinib and its equipotent metabolite CGP74588 were determined by standard non-compartmental methods, with PK Solutions 2.0 (Summit research Services, montrose, CO; www.summitPK.com). the maximum plasma concentration (C max ) and time to reach the maximum plasma concentration (T max ) were determined by visual inspection of the plasma concentration versus time data. the imatinib elimination rate constant (k e ) was obtained using nonlinear least-square regression of the terminal concentration versus time data. the imatinib area under the concentration versus time curve (auC) was calculated by the trapezoidal rule with extrapolation to infinity (auC 0-∞ ). the percentage of auC 0-∞ extrapolated beyond the last sample time (C last ) was calculated. Ideally, the percentage extrapolated is <20 %.
Statistical analysis
Whether or not calcium carbonate had a significant effect on the pharmacokinetics of imatinib was determined with SPSS 21.0 for Windows (SPSS Inc., Chicago, IL, uSa). T max was compared nonparametrically with the two-tailed exact Wilcoxon signed rank test (paired data). all other pharmacokinetic parameters were compared by paired t test after log transformation. Data were considered significantly different when P < 0.05.
an analysis of bioequivalence was performed by calculating the 90 % confidence intervals of the imatinib auC ratio and the C max ratio, based on log-transformed data. Equivalence limits were 80-125 % as defined previously [2] .
Results
twenty subjects were enrolled to obtain 11 evaluable subjects with complete data sets. reasons for subjects to fail screening included the following: elevated aSt/aLt; BmI > 31 kg/m 2 ; symptomatic urinary tract infection; hypertension; and high urine glucose. adverse events likely related to imatinib included dyspepsia (grade 2, N = 1; grade 1, N = 2) and nausea (grade 1, N = 1). the pharmacokinetic parameter estimates for imatinib are shown in table 1. the percentage of the auC extrapolated beyond C last was <8.2 % for imatinib, providing confidence in the auC 0-∞ values generated. Concentration versus time curves of imatinib and CGP74588 in the presence and absence of calcium carbonate, respectively, are shown in Fig. 1a .
Coadministration of calcium carbonate with imatinib did not result in statistically significant difference in imatinib plasma auC 0-∞ (P = 0.99) or C max (P = 0.89). the 90 % confidence intervals of the imatinib auC ratio (mean 1.00, 90 % CI 0.89-1.13) and the C max ratio (mean 1.01, 90 % CI 0.90-1.13) both fall well within the limits set for bioequivalence [2] . none of the other pharmacokinetic parameters for imatinib or CGP74588 were significantly affected by calcium carbonate (table 1; Fig. 1 ).
Discussion
this healthy volunteer study demonstrates that the use of calcium carbonate is not associated with a significant change in the pharmacokinetics of imatinib or its metabolite. Our result of no interaction is similar to results when imatinib was coadministered with a mg 2+ -al
3+
-based antacid [10] , or when nilotinib was coadministered with calcium carbonate (submitted). however, they are in contrast to data demonstrating that proton pump inhibitor use is associated with a nearly twofold decrease in dasatinib auC and C max [1] , a 27 % decrease in nilotinib C max , and a 34 % decrease in nilotinib auC [12] . Based on our results, a transient elevation in gastric ph, such as occurs with calcium carbonate and an abundance of calcium ions available for complexation, does not appear to limit imatinib absorption.
this study was not powered for bioequivalence; however, the 90 % CI of the log-transformed ratios of imatinib auC and C max fell within the bioequivalence limits, suggesting that the two modes of administration are equivalent.
Cancer patients are increasingly being treated with oral agents, often tyrosine kinase inhibitors (tKI) such as imatinib. the potential polypharmacy resulting from concomitant therapy with prescription or over-the-counter medications poses new challenges that need to be addressed. novel oral anticancer agents such as tKI are generally not curative and are administered chronically, and there have been numerous reports of exposure response relationships. In particular for imatinib, there is evidence that trough plasma concentrations are associated with clinical benefit in patients with advanced GISt and with response in patients with CmL [4, 8] . therefore, drug-drug interactions are likely to significantly impact the outcomes of therapy, and systematic evaluations of such interactions are critical. Both underexposure resulting in therapeutic failure and overexposure resulting in toxicity may be caused by seemingly harmless drug combinations. In conclusion, our results show that concomitant administration of the calcium carbonate is not associated with alterations in imatinib pharmacokinetics.
